New combo therapy targets tough-to-treat lung tumors
NCT ID NCT05888402
First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. The trial enrolls 50 adults aged 18-75 with tumors at least 5 cm wide or lymph nodes at least 2 cm. The main goal is to see how long patients live without the cancer growing, while also tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.